Department of Hematology, All India Institute of Medical Sciences, New Delhi, India.
Leuk Lymphoma. 2013 Apr;54(4):778-89. doi: 10.3109/10428194.2012.730614. Epub 2012 Oct 5.
This study analyzed the frequency of regulatory T cells (Tregs) in chronic lymphocytic leukemia (CLL) by multiparameter flow cytometric immunophenotyping. Patients showed significantly increased frequencies of Tregs as compared to controls, a significantly higher percentage than that identified by previous studies, possibly indicating a different prognosis of CLL in different parts of the world and, more precisely, a worse prognosis of CLL in the Indian population. A higher frequency of Tregs was also seen in advanced stage of disease with significantly reduced frequencies of Tregs in patients with CLL after chemotherapy. A significant proportion of CD127low/-FoxP3+ Tregs expressed only low levels of CD25. Thus, CD127 appears to be a better marker than CD25 for the identification of CD4+FoxP3+ T cells as potential Tregs. Our results suggest that the specificity and sensitivity of CD4+CD127low/- cells are comparable to those of CD4+FoxP3+, which is the gold standard, and can be used as an alternative. This novel flow cytometric antibody panel with fewer number of antibodies is cost-effective and can be used to enumerate Tregs in resource-limited settings.
本研究通过多参数流式细胞术免疫表型分析了慢性淋巴细胞白血病(CLL)中调节性 T 细胞(Tregs)的频率。与对照组相比,患者的 Tregs 频率明显升高,明显高于之前研究确定的比例,这可能表明 CLL 在世界不同地区的预后不同,更确切地说,CLL 在印度人群中的预后更差。在疾病晚期也观察到 Tregs 的频率更高,而化疗后 CLL 患者的 Tregs 频率显著降低。相当一部分 CD127low/-FoxP3+Tregs 仅表达低水平的 CD25。因此,与 CD25 相比,CD127 似乎是鉴定 CD4+FoxP3+T 细胞作为潜在 Tregs 的更好标记物。我们的研究结果表明,CD4+CD127low/-细胞的特异性和敏感性与作为金标准的 CD4+FoxP3+相当,可作为替代方法。这种新型流式细胞术抗体面板使用的抗体数量较少,具有成本效益,可用于在资源有限的环境中计数 Tregs。